N
Naomi De Silva
Researcher at Ottawa Hospital Research Institute
Publications - 14
Citations - 1409
Naomi De Silva is an academic researcher from Ottawa Hospital Research Institute. The author has contributed to research in topics: Oncolytic virus & Cancer cell. The author has an hindex of 12, co-authored 14 publications receiving 1247 citations. Previous affiliations of Naomi De Silva include University of Ottawa & Children's Hospital of Eastern Ontario.
Papers
More filters
Journal ArticleDOI
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Caroline J. Breitbach,James M. Burke,Derek J. Jonker,Derek J. Jonker,Joe Stephenson,Andrew R. Haas,Laura Q M Chow,Laura Q M Chow,Jorge Nieva,Tae-Ho Hwang,Anne Moon,Richard H. Patt,Adina Pelusio,Fabrice Le Boeuf,Joseph K. Burns,Joseph K. Burns,Laura Evgin,Laura Evgin,Naomi De Silva,Naomi De Silva,Sara Cvancic,Sara Cvancic,Terri Robertson,Ji Eun Je,Yeon Sook Lee,Kelley Parato,Jean-Simon Diallo,Aaron Fenster,Manijeh Daneshmand,Manijeh Daneshmand,John C. Bell,John C. Bell,David H. Kirn +32 more
TL;DR: It is shown in a clinical trial that JX-594 selectively infects, replicates and expresses transgene products in cancer tissue after intravenous infusion, in a dose-related fashion.
Journal ArticleDOI
Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
Caroline J. Breitbach,Rozanne Arulanandam,Naomi De Silva,Steve H. Thorne,Richard H. Patt,Manijeh Daneshmand,Anne Moon,Carolina S. Ilkow,James M. Burke,Tae-Ho Hwang,Jeong Heo,Mong Cho,Hannah Chen,Fernando A. Angarita,Christina L. Addison,J. Andrea McCart,John C. Bell,David H. Kirn +17 more
TL;DR: The JX-594 platform technology opens up the possibility of multifunctional engineered vaccinia products that selectively target and infect tumor-associated endothelial cells, as well as cancer cells, resulting in transgene expression, vasculature disruption, and tumor destruction in humans systemically.
Journal ArticleDOI
Targeting Tumor Vasculature With an Oncolytic Virus
Caroline J. Breitbach,Naomi De Silva,Theresa Falls,Usaf E. Aladl,Laura Evgin,Jennifer M Paterson,Yang Yang Sun,Dominic G. Roy,Julia L Rintoul,Manijeh Daneshmand,Kelley Parato,Marianne M. Stanford,Brian D. Lichty,Aaron Fenster,David H. Kirn,Harold L. Atkins,John C. Bell +16 more
TL;DR: It is shown here for the first time that VSV directly infects and destroys tumor vasculature in vivo but leaves normal vasculatures intact, demonstrating that the therapeutic activity of an OV can go far beyond simple infection and lysis of malignant cells.
Journal ArticleDOI
A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
Tae-Ho Hwang,Anne Moon,James M. Burke,Antoni Ribas,Joe Stephenson,Caroline J. Breitbach,Manijeh Daneshmand,Naomi De Silva,Kelley Parato,Jean-Simon Diallo,Yeon-Sook Lee,Ta-Chiang Liu,John C. Bell,David H. Kirn +13 more
TL;DR: A mechanistic proof-of-concept clinical trial was performed at a low dose equivalent to ≤10% of the maximum-tolerated dose (MTD) in other clinical trials, which demonstrated JX-594 replication, oncolysis, and expression of both transgenes were demonstrated.
Journal ArticleDOI
VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection
Rozanne Arulanandam,Cory Batenchuk,Fernando A. Angarita,Kathryn Ottolino-Perry,Sophie Cousineau,Amelia Mottashed,Emma Burgess,Theresa Falls,Naomi De Silva,Jovian Tsang,Grant A. Howe,Marie-Claude Bourgeois-Daigneault,David P. Conrad,Manijeh Daneshmand,Caroline J. Breitbach,David H. Kirn,Leda Raptis,Subash Sad,Harold L. Atkins,Michael S. Huh,Jean-Simon Diallo,Brian D. Lichty,Carolina S. Ilkow,Fabrice Le Boeuf,Christina L. Addison,J. Andrea McCart,J. Andrea McCart,John C. Bell +27 more
TL;DR: In vivo suppression of VEGF signaling diminishes PRD1-BF1/Blimp1 expression in tumor vasculature and inhibits intravenously administered oncolytic vaccinia delivery to and consequent spread within the tumor.